Diagnostic and prognostic values of N-terminal pro-C type natriuretic peptide in patients with COPD and pulmonary hypertension
https://doi.org/10.18093/0869-0189-2015-25-6-693-697
Abstract
The aim of this study was to investigate diagnostic and prognostic values of Nterminal proC type natriuretic peptide in patients with stage II – IV chronic obstructive pulmonary disease (COPD) (GOLD, 2011).
Methods. Patients with stage II – IV COPD (n = 47; 44 males, mean age, 59.49 ± 0.63 years; disease duration, 13.7 ± 0.63 years; smoking history, 23.09 ± 0.93 packyears; body mass index, 27.22 ± 9.06 kg / m–2) were involved in the study. The patients were divided according to presence or absence of pulmonary hypertension (PH): patients without PH (n = 21; systolic pulmonary artery pressure (sPAP) < 40 mmHg), patients with mild PH (n = 16, sPAP 40 – 55 mmHg) and patients with severe PH (n = 10; sPAP > 55 mmHg).
Results. NTproCNP levels differed significantly between patients without PH (1.42 ± 0.03 pg / mL), patients with mild PH (4.14 ± 0.51 pg / mL) and patients with severe PH (5.26 ± 0.21 pg / mL) (p1–2 = 0.001; p2–3 = 0.001; p1–3 < 0.001). sPAP was related to NTproCNP level (r = 0.53; p < 0.05).
Conclusion. NTproCNP had a high diagnostic value for predicting severe and nonsevere PH in COPD patients.
About the Authors
V. V. Gaynitdinova
Bashkir State Medical University: 3, Lenina str., Ufa, 450000, Bashkortostan Republic, Pussia
Russian Federation
Russian Federation
PhD, Associate Professor at Department of Therapy and Clinical Pharmacology, Bashkir State Medical University; tel.:
(347) 2722385
L. A. Sharafutdinova
Bashkir State University: 32, Z.Validi str., Ufa, 450076, Bashkortostan Republic, Russia
Russian Federation
Russian Federation
MD, Professor, Head of Clinical Division, Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia; tel.: (495) 4655264
S. N. Avdeev
Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia: 32, build. 4, 11th Parkovaya str., Moscow, 105077, Russia
Russian Federation
Russian Federation
PhD in Biology, Associate Professor at Department of Human Physiology and Zoology, Biological Faculty, Bashkir State University; tel.: (347) 2299671
R. Ya. Gubaydullina
State City Clinical Hospital N 21; 3g, Lesnoy passage, Ufa, 450071, Bashkortostan Republic, Russia
Russian Federation
Russian Federation
a physician at Department of Functional Diagnosis, State City Clinical Hospital N 21; tel.: (917) 7754070
References
1. Weitzenblum E., Hirth C., Ducolone A. et al. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax. 1981; 36: 752–758.
2. Chaouat A., Bugnet A.S., Kadaoui N. et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005; 172: 189–194.
3. Andersen K.H., Iversen M., Kjaergaard J. et al. Prevalence, predictors and survival in pulmonary hypertension related to endstage chronic obstructive pulmonary disease. Heart Lung Transplant. 2012; 31: 373–380.
4. Burrows B. Arterial oxygenation and pulmonary hemodynamics in patients with chronic airways obstruction. Am. Rev. Respir. Dis. 1974; 110: 64–70.
5. Wright J.L. Relationship of pulmonary arterial pressure and air flow obstruction to emphysema. J. Appl. Physiol. 1993; 74: 1320–1324.
6. Santos S., Peinado V.I., Ramirez J. et al. Characterization of pulmonary vascular remodeling in smokers and patients with mild COPD. Eur. Respir. J. 2002; 19: 632–638.
7. Hale K.A, Ewing S.L., Gosnell B.A. et al. Lung disease in long term cigarette smokers with and without chronic airflow obstruction. Am. Rev. Respir. Dis. 1984; 130: 716–721.
8. Peinado V.I., Barbera J.A., Abate P. et al. Infl ammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 159: 1605–1611.
9. DinhXuan A.T., Higenbottam T.W., Clelland C.A. et al. Impairment of endotheliumdependent pulmonaryartery relaxation in chronic obstructive lung disease. N. Engl. J. Med. 1991; 324: 1539–1547.
10. Peinado V.I., Barbera J.A., Ramirez J. et al. Endothelial dysfunction in pulmonary arteries of patients with mild COPD. Am. J. Physiol. 1998; 274: 908–913.
11. Santos S., Peinado V.I., Ramirez J. et al. Enhanced expression of vascular endothelial growth factor in pulmonary arteries of smokers and patients with moderate chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2003; 167: 1250–1256.
12. Sellitti D.F. Regulation of Ctype natriuretic peptide expression. Peptides. 2011; 32: 1964–1971.
13. Cazzola M., MacNee W., Martinez F.J. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur. Respir. J. 2008; 31: 416–469.
14. Seeger W., Adir Y., Barber? J.A. et al. Pulmonary hypertension in chronic lung diseases. J. Am. Coll. Cardiol. 2013; 62 (25, Suppl. D): 110–116.
15. Quanjer Ph.H., Tammelling G., Gotes J.E. et al. Lung volumes and forced ventilator flows. Eur. Respir. J. 1993; 6 (Suppl. 16): 5–40.
16. Chaouat A., Naeije R., Weitzenblum E. Pulmonary hyperten sionin COPD. Eur. Respir. J. 2008; 32: 1371–1385.
17. Scotland R.S., Ahluwalia A., Hobbs A.J. Ctype natriuretic peptide in vascular physiology and disease. Pharmacol. Ther. 2005; 105: 85–93.
18. Almeida F.M., Suzuki M., Scarborough R.M. et al. Clearance function of type C receptors of atrial natriuretic factor in rats. Am. J. Physiol. 1989; 256: 469–475.
19. Vlachopoulos C., Ioakeimidis N., TerentesPrintzios D. et al. Aminoterminal proCtype natriuretic peptide is associated with arterial stiffness, endothelial function and early atheroscle rosis. Atherosclerosis. 2010; 211: 649–655
20. Soeki T., Kishimoto I., Okumura H. et al. Ctype natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. J. Am. Coll. Cardiol. 2005; 5: 608–616.
21. Suga S., Nakao K., Itoh H. et al. Endothelial production of C type natriuretic peptide and its marked augmentation by trans forming growth factorbeta. Possible existence of «vascular natriuretic peptide system». J. Clin. Invest. 1992; 90: 1145–1149.
22. Naruko T., Itoh A., Haze K. et al. Ctype natriuretic peptide and natriuretic peptide receptors are expressed by smooth muscle cells in the neointima after percutaneous coronary intervention. Atherosclerosis. 2005;181: 241–250.
23. Peltonen T.O., Taskinen P., Soini Y. et al. Distinct downregulation of Ctype natriuretic peptide system in human aortic valve stenosis. Circulation. 2007; 116: 1283–1289.
24. Christoffersen C., Bartels E.D., Nielsen L.B. Heart specific up regulation of genes for Btype and Ctype natriuretic peptide receptors in diabetic mice. Eur. J. Clin. Invest. 2006; 36: 69–75.
25. Suga S., Itoh H., Komatsu Y. et al. Cytokineinduced Ctype natriuretic peptide (CNP) secretion from vascular endothelial cellsevidence for CNP as a novel autocrine / paracrine regulator from endothelial cells. Endocrinology. 1993; 133: 3038–3041.
26. Cargill R.I., Barr C.S., Coutie W.J. et al. Ctype natriuretic peptide levels in cor pulmonale and in congestive heart failure. Thorax. 1994; 49: 1247–1249.
27. Неклюдова Г.В., Авдеев С.Н., Баймаканова Г.Е. Хроническая обструктивная болезнь легких и легочная гипертензия: мозговой натрийуретический пептид как маркер легочной гипертензии. Пульмонология. 2013; 3: 31–35. / Neklyudova G.V., Avdeev S.N., Baymakanova G.E. Chronic obstructive pulmonary disease and pulmonary hypertension: brain natriuretic peptide as a marker of pulmonary hyperten sion. Pul'monologiya. 2013; 3: 31–35 (in Russian).
Review
For citations:
Gaynitdinova V.V., Sharafutdinova L.A., Avdeev S.N., Gubaydullina R.Ya. Diagnostic and prognostic values of N-terminal pro-C type natriuretic peptide in patients with COPD and pulmonary hypertension. PULMONOLOGIYA. 2015;25(6):693-697. (In Russ.) https://doi.org/10.18093/0869-0189-2015-25-6-693-697
Views:
683
Email this article 